Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fanconi anemia group G protein (FANCG) is a core component of the Fanconi anemia (FA) repair pathway, responsible for repairing DNA interstrand cross-links (ICLs) that block DNA replication. FANCG is one of several proteins that together form the FA core complex, which facilitates the monoubiquitination of FANCD2 and FANCI, activating downstream DNA repair. FANCG is essential for maintaining genomic integrity by preventing chromosomal breakage during replication stress. Deficiency or mutation in FANCG causes Fanconi anemia complementation group G, leading to a phenotype of bone marrow failure, developmental abnormalities, and increased cancer risk, especially for acute myeloid leukemia and various solid tumors. FANCG-deficient cells are hypersensitive to DNA cross-linking agents (e.g., cisplatin, mitomycin C). There are no direct therapies targeting FANCG, but its genetic status is valuable for diagnosis, prognosis, and guiding the use of DNA-damaging chemotherapeutics.
Not applicable, as there are no direct drugs targeting FANCG; indirect effects relate to hypersensitivity to cross-linking chemotherapies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fanconi anemia group G protein (FANCG).